US 2026/0308278 A1Published application

ANTIBODY THAT BINDS TO C3bBb

AssigneeHoffmann-La Roche Inc.

InventorsDavide BERTOLDO, Joachim BUTZER, Sebastian FENN, Alexander FIDLER, Anton JOCHNER, Eloed KOERTVELY, Jean-Luc MARY, Sebastian PIRNER

Life of this patent

Estimating the term…

Abstract

The present invention relates to anti-C3bBb antibodies and methods of using the same.

Claims7

Dependent claims

An antibody that binds to human C3bBb, comprising

i) a heavy chain variable domain (VH) comprising (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:449;
(b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:450;
and (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:451, and a light chain variable domain (VL) comprising (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:452;
(e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO:453;
and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:454;
ii) a heavy chain variable domain (VH) comprising (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:455;
(b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:456;
and (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:457, and a light chain variable domain (VL) comprising (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:458;
(e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO:459;
and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:460;
iii) a heavy chain variable domain (VH) comprising (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:461;
(b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:462;
and (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:463, and a light chain variable domain (VL) comprising (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:464;
(e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO:465;
and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:466;
iv) a heavy chain variable domain (VH) comprising (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:467;
(b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:468;
and (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:469, and a light chain variable domain (VL) comprising (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:470;
(e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO:471;
and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:472;
v) a heavy chain variable domain (VH) comprising (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:473;
(b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:474;
and (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:475, and a light chain variable domain (VL) comprising (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:476;
(e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO:477;
and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:478 (corresponding to antibody #5, P1AG9391);
vi) a heavy chain variable domain (VH) comprising (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:479;
(b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:480;
and (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:481, and a light chain variable domain (VL) comprising (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:482;
(e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO:483;
and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:484;
or
vii) a heavy chain variable domain (VH) comprising (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:485;
(b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:486;
and (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:487, and a light chain variable domain (VL) comprising (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:488;
(e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO:489;
and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:490.

33 more elements

Dependencies are inferred from the claim text.

Facts

Application: 19/713,603Filed 18 Jun 2026
Priority: EP 23199373.425 Sep 2023
Published: 8 Oct 2026
Term ends: Not estimatedThe source records don’t support an estimate.

Classification8 codes

C07K 16/40
Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies: against enzymes
C07K 2317/33
Characterized by aspects of specificity or valency: crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
C07K 2317/565
Variable region, i.e. VH and/or VL: complementarity determining region [CDR]
C07K 2317/567
Variable region, i.e. VH and/or VL: framework region [FR]

Family

Application19/575,890Continuation · filed 23 Mar 2026
Application19/713,603Continuation
US 2026/0308278 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

Building an agent or pulling many patents? Use the API or MCP server instead of scraping pages. Get an API key

patentgrep

Loading patent…

An antibody that binds to human C3bBb, comprising

i) a heavy chain variable domain (VH) comprising (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:449;
(b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:450;
and (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:451, and a light chain variable domain (VL) comprising (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:452;
(e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO:453;
and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:454;
ii) a heavy chain variable domain (VH) comprising (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:455;
(b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:456;
and (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:457, and a light chain variable domain (VL) comprising (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:458;
(e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO:459;
and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:460;
iii) a heavy chain variable domain (VH) comprising (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:461;
(b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:462;
and (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:463, and a light chain variable domain (VL) comprising (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:464;
(e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO:465;
and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:466;
iv) a heavy chain variable domain (VH) comprising (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:467;
(b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:468;
and (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:469, and a light chain variable domain (VL) comprising (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:470;
(e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO:471;
and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:472;
v) a heavy chain variable domain (VH) comprising (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:473;
(b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:474;
and (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:475, and a light chain variable domain (VL) comprising (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:476;
(e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO:477;
and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:478 (corresponding to antibody #5, P1AG9391);
vi) a heavy chain variable domain (VH) comprising (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:479;
(b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:480;
and (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:481, and a light chain variable domain (VL) comprising (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:482;
(e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO:483;
and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:484;
or
vii) a heavy chain variable domain (VH) comprising (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:485;
(b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:486;
and (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:487, and a light chain variable domain (VL) comprising (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:488;
(e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO:489;
and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:490.

33 more elements

Facts

Application

19/713,603Filed 18 Jun 2026

Priority

EP 23199373.425 Sep 2023

Published

8 Oct 2026

Term ends

Not estimatedThe source records don’t support an estimate.

Classification8 codes

C07K 16/40
Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies: against enzymes
C07K 2317/33
Characterized by aspects of specificity or valency: crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
C07K 2317/565
Variable region, i.e. VH and/or VL: complementarity determining region [CDR]
C07K 2317/567
Variable region, i.e. VH and/or VL: framework region [FR]